These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series. Ioja E; Tóth G; Benyhe S; Tourwe D; Péter A; Tömböly C; Borsodi A Neurosignals; 2005; 14(6):317-28. PubMed ID: 16772734 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Takeuchi K; Holloway WG; McKinzie JH; Suter TM; Statnick MA; Surface PL; Emmerson PJ; Thomas EM; Siegel MG; Matt JE; Wolfe CN; Mitch CH Bioorg Med Chem Lett; 2007 Oct; 17(19):5349-52. PubMed ID: 17720493 [TBL] [Abstract][Full Text] [Related]
7. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans. Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876 [TBL] [Abstract][Full Text] [Related]
8. Electron impact mass spectrometry of substituted 1,3,8-triazaspiro[4,5]decan-4-ones. Danieli B; Rubino FM; Zecca L Biomed Environ Mass Spectrom; 1989 Nov; 18(11):1000-4. PubMed ID: 2620151 [TBL] [Abstract][Full Text] [Related]
9. ORL1 receptor ligands: structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones. Röver S; Wichmann J; Jenck F; Adam G; Cesura AM Bioorg Med Chem Lett; 2000 Apr; 10(8):831-4. PubMed ID: 10782696 [TBL] [Abstract][Full Text] [Related]
10. Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding. Metwally KA; Dukat M; Egan CT; Smith C; DuPre A; Gauthier CB; Herrick-Davis K; Teitler M; Glennon RA J Med Chem; 1998 Dec; 41(25):5084-93. PubMed ID: 9836624 [TBL] [Abstract][Full Text] [Related]
11. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists. Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176 [TBL] [Abstract][Full Text] [Related]
12. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group. Traynor JR; Guo L; Coop A; Lewis JW; Woods JH J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829 [TBL] [Abstract][Full Text] [Related]
13. In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Peng X; Knapp BI; Bidlack JM; Neumeyer JL Bioorg Med Chem; 2007 Jun; 15(12):4106-12. PubMed ID: 17433695 [TBL] [Abstract][Full Text] [Related]
14. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine. Wentland MP; VanAlstine M; Kucejko R; Lou R; Cohen DJ; Parkhill AL; Bidlack JM J Med Chem; 2006 Sep; 49(18):5635-9. PubMed ID: 16942039 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. Peng X; Knapp BI; Bidlack JM; Neumeyer JL J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of a series of N-alkyl benzomorphans in cell lines expressing transfected delta- and mu-opioid receptors. Abood ME; Noel MA; Carter RC; Harris LS Biochem Pharmacol; 1995 Sep; 50(6):851-9. PubMed ID: 7575648 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors. Kazmierski W; Wire WS; Lui GK; Knapp RJ; Shook JE; Burks TF; Yamamura HI; Hruby VJ J Med Chem; 1988 Nov; 31(11):2170-7. PubMed ID: 2903246 [TBL] [Abstract][Full Text] [Related]
18. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC. VanAlstine MA; Wentland MP; Cohen DJ; Bidlack JM Bioorg Med Chem Lett; 2007 Dec; 17(23):6516-20. PubMed ID: 17935988 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975 [TBL] [Abstract][Full Text] [Related]